www.bloomberg.com
Oxford Biomedica announced it is in preliminary discussions with Swedish investment firm EQT regarding a potential cash acquisition offer. The gene and cell therapy company noted that there can be no certainty that an offer will be made or on what terms. If a firm offer is made, it would likely be structured as an all-cash transaction. Trading in Oxford Biomedica shares was suspended pending further announcements.
Read More
